Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · Belgium
Declared costs: €200K+ a year · in the register since 2015
NGO · Belgium
Declared costs: not declared · in the register since 2010
Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
UCB · filed 26 Apr 2021 · source
UCB has a fundamental commitment to enabling people living with severe diseases, their caregivers & families to live their best lives. We continuously innovate to bring differentiated solutions with unique outcomes, which help specific patients achieve their life goals. To deliver on that commitment now and into the future, sustainability is a strategic imperative for us.
European Public Health Alliance (EPHA) · filed 27 Apr 2021 · source
The revision of the EU general pharmaceuticals legislation should aim to address the problems of availability, accessibility and affordability of medicines as well as to incentivise meaningful, public health needs-driven biomedical innovation. Put simply, it should serve the goal of having better and affordable medicines for those who need them.
European Public Health Alliance (EPHA) · filed 18 Dec 2020 · source
Small biotechs, university spin-offs and other research institutions are now at the heart of pharmaceutical R&D conducting the early-stage research, financed by venture capitalists, hedge funds and private equity. Large pharmaceutical companies perform less research in-house while they scan the horizon for promising products and companies. They subsequently acquire them.
UCB · filed 6 Jan 2021 · source
UCB is dedicated to finding unique solutions for diseases with high degree of patient need. Regardless of the population size, it’s patients’ needs that direct our efforts. Our ambition for patients relies on our ability to innovate & bring differentiated solutions with unique outcomes that help specific patients achieve their goals.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.